TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Teclistamab receives EMA conditional marketing authorization

By Chris Barton

Share:

Aug 26, 2022

Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.


Following its recommendation for conditional marketing approval from the Committee for Medicinal Products for Human Use (CHMP) in July 2022, on August 24, 2022, teclistamab was granted conditional marketing authorization from the European Commission as monotherapy for adult patients with relapsed/refractory multiple myeloma (RRMM).1 This is based on the results of the MajesTEC-1 phase I/II trials (NCT03145181 and NCT04557098),1 as covered previously by the Multiple Myeloma Hub (available here).

Teclistamab is licensed for patients who have previously been treated at least once with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody, and have demonstrated progression on the last agent.1 The announcement represents the first global approval of teclistamab for the treatment of RRMM, following an accelerated approval pathway supported by the European Medicines Agency Priority Medicines Program (PRIME). In addition, teclistamab is the first bispecific antibody approved for the treatment of MM.1

Key findings from the MajesTEC-1 study include the following1:

  • The median progression-free survival was 11.3 months (95% confidence interval, 8.817.1).
  • The median overall survival was 18.3 months (95% confidence interval, 15.1 – not estimable).

 No safety concerns were raised, and further efficacy and safety data can be found here.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content